Liquid Biopsy Market Companies Analysis

The global liquid biopsy market is witnessing rapid expansion, driven by the increasing need for non-invasive cancer diagnostics and precision medicine. The industry is projected to grow from US$ 4.29 billion in 2024 to US$ 15.46 billion by 2033, reflecting a strong CAGR of 15.30% between 2025 and 2033.

Liquid biopsy technology enables the detection of genetic alterations and cancer biomarkers from blood samples, eliminating the need for invasive surgical biopsies. By analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other molecular fragments, clinicians can diagnose cancer earlier, monitor tumor progression in real time, and evaluate treatment response more effectively.

With rising global cancer prevalence, advancements in genomics, and increasing demand for personalized therapies, liquid biopsy is rapidly transforming oncology diagnostics and reshaping healthcare delivery worldwide.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=liquid-biopsy-market-competitive-landscape-p.php

Competitive Landscape of the Liquid Biopsy Market

The market is characterized by strong innovation, strategic collaborations, and regulatory approvals. Companies are investing heavily in next-generation sequencing (NGS), AI-driven data analytics, and companion diagnostics to enhance clinical utility and expand global reach.

Below is an analysis of leading companies shaping the liquid biopsy ecosystem.

Leading Companies in the Liquid Biopsy Market

Roche Diagnostics

Established: 1896
Headquarters: Switzerland

Roche Diagnostics, part of F. Hoffmann-La Roche Ltd., is a global leader in molecular diagnostics and in-vitro testing systems. The company develops advanced diagnostic instruments, workflow solutions, and molecular reagents for oncology applications. Its strong global presence and commitment to research innovation position it as a dominant player in liquid biopsy technologies.

Exact Sciences Corporation

Established: 1995
Headquarters: United States
Revenue (2023): US$ 2.8 Billion

Exact Sciences specializes in cancer diagnostics, including non-invasive DNA-based screening solutions. The company’s portfolio includes stool-based DNA tests and genomic expression assays for colorectal, breast, and prostate cancers. Its expansion into liquid biopsy platforms strengthens its precision oncology footprint.

Thermo Fisher Scientific Inc.

Established: 2006
Headquarters: United States
Revenue (2023): US$ 42.9 Billion

Thermo Fisher Scientific provides analytical instruments, reagents, and molecular diagnostic solutions widely used in liquid biopsy workflows. Its product portfolio supports next-generation sequencing, nucleic acid analysis, and advanced molecular profiling, serving pharmaceutical firms, research institutions, and diagnostic laboratories worldwide.

Bio-Rad Laboratories Inc.

Established: 1952
Headquarters: United States
Revenue (2023): US$ 2.6 Billion

Bio-Rad develops digital PCR systems, reagents, and molecular diagnostic tools crucial for mutation detection and gene expression analysis. Its technologies are widely adopted for detecting rare genetic events, strengthening its role in the liquid biopsy segment.

Biocept Inc.

Established: 1997
Headquarters: United States

Biocept focuses on circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) testing for solid tumors, including breast, lung, colorectal, and prostate cancers. Its proprietary OncoCEE and Target Selector technologies enhance rare cell capture and genetic characterization capabilities.

Recent Market Developments

Laboratory Corporation of America Holdings (Labcorp)

In April 2025, Labcorp expanded its precision oncology portfolio with two new liquid biopsy offerings:

·        Labcorp Plasma Detect, designed to assess recurrence risk in stage III colon cancer patients.

·        PGDx elio plasma focus Dx, the first FDA-authorized kitted liquid biopsy test for pan-solid tumors.

These innovations strengthen Labcorp’s position in molecular diagnostics and precision medicine.

Tempus AI Inc.

In January 2025, Tempus AI launched xT CDx, an FDA-approved NGS-based in vitro diagnostic test available nationwide. The platform enables comprehensive genomic profiling, supporting clinicians in identifying actionable mutations for personalized cancer therapies.

Sustainability and ESG Initiatives

Natera Inc.

Natera demonstrates strong environmental, social, and governance (ESG) leadership:

·        Reduced kit waste by 31% in 2024, eliminating nearly 1 million pounds of waste.

·        Achieved approximately 8% reduction in Scope 1 and 2 emissions since 2021.

·        Facilities in Austin and San Carlos earned My Green Lab certifications.

·        Conducted full greenhouse gas accounting for scopes 1, 2, and 3 in collaboration with climate experts.

These efforts highlight the integration of sustainability into genomic diagnostics operations.

Johnson & Johnson

Johnson & Johnson aims to:

·        Achieve 100% renewable electricity by 2025.

·        Reduce Scope 1 and 2 emissions by 44% by 2030.

·        Reach net-zero emissions across its value chain by 2045.

By 2024, approximately 88% of its electricity consumption globally came from renewable sources, underscoring its commitment to environmental stewardship.

Product Profile: QIAGEN N.V.

QIAGEN provides comprehensive liquid biopsy solutions, including:

·        PAXgene Urine Liquid Biopsy Set for cfDNA stabilization.

·        QIAamp Circulating Nucleic Acid Kit for manual cfDNA extraction.

·        QIAseq cfDNA All-in-One Kit optimized for NGS-based genomic profiling.

These solutions support accurate molecular diagnostics across oncology applications.

SWOT Analysis

Guardant Health Inc.

Strength:
Market leadership in non-invasive cancer diagnostics with Guardant360 and GuardantOMNI platforms. Strong IP portfolio with over 230 patents enhances competitive advantage.

Opportunity:
Expansion of multi-cancer early detection tests such as Shield, offering potential for broader screening applications and global market penetration.

Illumina Inc.

Strength:
Global leadership in next-generation sequencing platforms such as NovaSeq and MiSeq, providing scalable genomic analysis solutions.

Opportunity:
Growing demand for precision medicine, oncology diagnostics, and companion diagnostics presents significant expansion potential.

Market & Forecast Outlook

Historical Trends

The liquid biopsy market has evolved from early research applications to mainstream oncology diagnostics. Regulatory approvals and technological advancements have accelerated adoption.

Forecast Analysis

With a projected CAGR of 15.30% through 2033, market growth will be driven by:

·        Increasing cancer incidence rates.

·        Wider clinical adoption of NGS-based tests.

·        Integration of AI-driven genomic analytics.

·        Expansion of companion diagnostics in pharmaceutical partnerships.

Market Share Analysis

Leading players such as Roche, Guardant Health, Illumina, Thermo Fisher Scientific, and Exact Sciences dominate due to technological innovation, global distribution networks, and regulatory approvals.

Comprehensive Company Coverage

Detailed analysis—including company overview, key leadership, recent developments, mergers and acquisitions, sustainability initiatives, product benchmarking, SWOT analysis, and revenue performance—is available for the following organizations:

·        Guardant Health Inc.

·        Foundation Medicine Inc. (Roche)

·        Natera Inc.

·        Illumina Inc.

·        Exact Sciences Corporation

·        Tempus AI Inc.

·        Thermo Fisher Scientific Inc.

·        Bio-Rad Laboratories Inc.

·        QIAGEN N.V.

·        Caris Life Sciences

·        MDxHealth SA

·        Biocept Inc.

·        Johnson & Johnson (Janssen Diagnostics)

·        Laboratory Corporation of America Holdings (Labcorp)

·        Epigenomics AG

·        F. Hoffmann-La Roche Ltd.

Final Thoughts

The liquid biopsy market represents one of the most transformative advancements in modern oncology diagnostics. With projections indicating growth from US$ 4.29 billion in 2024 to US$ 15.46 billion by 2033, the sector is positioned for sustained double-digit expansion.

Technological innovation, regulatory support, and the shift toward precision medicine are redefining cancer detection and monitoring. As industry leaders continue to enhance genomic profiling accuracy, improve patient comfort, and integrate sustainability into operations, liquid biopsy is set to become a cornerstone of future cancer care worldwide.